• 1
    Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 85208530.
  • 2
    Tefferi A,Vaidya R,Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 13561363.
  • 3
    Pardanani A,Finke C,Lasho TL, et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 2011; 26: 693699.
  • 4
    Gangat N,Caramazza D,Vaidya R, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Official J Am Soc Clin Oncol 2011; 29: 392397.
  • 5
    Greenberg P,Cox C,LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 20792088.
  • 6
    Kornblau SM,McCue D,Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 42514261.
  • 7
    Pardanani A,Begna K,Finke C, et al. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011; 86: 343345.
  • 8
    Verstovsek S,Kantarjian H,Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 11171127.
  • 9
    Vardiman JW,Thiele J,Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937951.
  • 10
    Barosi G,Mesa RA,Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post- essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437438.
  • 11
    Schall TJ,Bacon K,Camp RD, et al. Human macrophage inflammatory protein alpha (MIP-1α) and MIP-1β chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177: 18211826.
  • 12
    Burger JA,Quiroga MP,Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113: 30503058.
  • 13
    Ponader S,Chen SS,Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 11821189.
  • 14
    Sivina M,Hartmann E,Kipps TJ, et al. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011; 117: 16621669.